SILTISS is dedicated to the development, production and marketing of non-animal biomimetic biomaterials, which promote and support tissue regeneration processes.
The initial applications relate to bone substitutes for the orthopedic and dental sectors as well as maxillofacial surgery.
The technology provided by SILTISS is protected by several patents and is the result of a close partnership with Inserm.
The team is led by Didier Letourneur, CNRS Research Director and Director of U1148 Inserm, located in Paris, and awarded the George Winter Prize by the European society of biomaterials.
The quality management system follows the requirements of the medical device regulation (ISO 13485) which guarantees the marketing of safe and effective products.
Natural hydrogels of
non-animal origin
Biomaterials that are biocompatible and of variable porosity
Biodegradable and biomimetic environment
100% developed and produced in France